Education · GLP-1 medications
The oral semaglutide pill (Wegovy pill): what it is and how it compares
A once-daily semaglutide tablet is now approved for weight loss. This is a calm, balanced explainer of what it is, what the trial showed, and how it fits into the wider landscape of semaglutide — including how it differs from what WeightlessRx prescribes.
Last updated: June 16, 2026
Direct answer
In December 2025, the FDA approved the first oral GLP-1 pill for weight loss — a once-daily tablet form of semaglutide, marketed as the Wegovy pill by Novo Nordisk, which launched in the U.S. in early January 2026. In its main trial, the pill produced an average weight loss of about 14% over 64 weeks (about 17% among people who stayed on treatment). It is a brand-name prescription product and is not the same as the compounded semaglutide WeightlessRx prescribes.
A note on what we prescribe. WeightlessRx prescribes compounded semaglutide and compounded tirzepatide — the active ingredients, delivered as injections through licensed U.S. pharmacies. WeightlessRx does not prescribe or sell the brand-name Wegovy pill. Compounded medications are prepared by licensed U.S. pharmacies and are not reviewed by the FDA for safety, quality, or efficacy. This page is educational and is not medical advice.
What is the oral semaglutide pill?
The oral semaglutide pill is a once-daily tablet form of semaglutide — the same active ingredient as the long-established semaglutide injection. It is the first oral GLP-1 medication approved for chronic weight management. The FDA approved it in December 2025, and it launched in the U.S. in early January 2026.¹
It is sold under the brand name Wegovy pill by Novo Nordisk. Beyond weight management, it is also indicated to reduce the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease.¹ ² It uses a 1.5 mg starting dose and a 25 mg treatment dose, reached through a gradual dose-escalation schedule.¹ ³
Plain definition. It's semaglutide in a daily pill instead of a weekly shot — a brand-name product made by Novo Nordisk, distinct from the compounded semaglutide that WeightlessRx prescribes.
How well does it work?
The approval was supported by the OASIS 4 trial — a 64-week, randomized, double-blind, placebo-controlled study of 307 adults with obesity or overweight plus at least one weight-related condition, excluding people with diabetes.³ Two figures are commonly reported, and it is worth understanding both:
~14% average (treatment-policy)
Participants lost an average of about 14% of body weight (13.6%) regardless of whether they stayed fully on treatment, versus about 2% (2.2%) on placebo. This is the more real-world number.³
~17% average (on treatment)
Among those who stayed fully on treatment, average weight loss was about 17% (16.6%), versus about 3% (2.7%) on placebo.³
~1 in 3 lost 20%+
Roughly one in three adherent participants lost 20% or more of their body weight, versus under 3% on placebo.³
The treatment-policy figure (~14%) is generally the more realistic expectation, because it counts everyone enrolled — including people who reduced or stopped the medication — rather than only those who stayed fully on it.³
Individual results vary. These are average results from a 64-week clinical trial in a specific population and are not a prediction of any individual's outcome.
How is the pill different from the injection?
The most visible difference is format and frequency. The Wegovy pill is taken once daily; the original Wegovy injection is taken once weekly. Novo Nordisk states that the pill's weight-loss magnitude is comparable to the 2.4 mg injection — though, importantly, that is based on separate trials rather than a single head-to-head comparison.¹ ²
| Feature | Wegovy pill (oral semaglutide) | Semaglutide injection |
|---|---|---|
| Format | Oral tablet | Subcutaneous injection |
| How often | Once daily | Once weekly |
| How it's taken | Oral semaglutide is typically taken on an empty stomach with a small sip of plain water, before eating or taking other medications. Follow your prescribing label. | Injected on the same day each week, with or without food. |
| Treatment dose | 25 mg | 2.4 mg (brand maintenance dose) |
| Regulatory status | FDA-approved brand-name product (Novo Nordisk) | Brand versions are FDA-approved; compounded versions are not FDA-reviewed |
Neither format is inherently "better" — they suit different people. Some prefer a daily pill and the specific routine it requires; others prefer a once-weekly injection they rarely have to think about. The right choice depends on a person's preferences, medical history, and a clinician's judgment.
How does this relate to what WeightlessRx offers?
Here is the plain version. The Wegovy pill is a brand-name product made by Novo Nordisk. WeightlessRx prescribes compounded semaglutide, which uses the same active ingredient but is a different product with a different regulatory status — it is prepared by licensed U.S. compounding pharmacies, is not FDA-reviewed, and is delivered as an injection rather than a tablet.
Both are forms of semaglutide. They are not interchangeable, and WeightlessRx does not offer the pill. If you're weighing your options, the most useful next step is to understand semaglutide itself — see our complete guide to semaglutide and our semaglutide vs. tirzepatide comparison — and then talk with a clinician about what fits you.
Side effects and safety
In the trial, the most common adverse events were gastrointestinal — nausea, diarrhea, and vomiting — consistent with the side-effect profile of the semaglutide injection.³ For practical management strategies, see our guide to GLP-1 side effects.
As with any GLP-1 medication, the full safety picture matters. GLP-1 medications are prescription drugs that should be taken only under the supervision of a licensed clinician. They carry risks including, but not limited to, thyroid C-cell tumors (including thyroid cancer) and medullary thyroid carcinoma (MTC), pancreatitis, gallbladder issues, and hypoglycemia. Tell your clinician if you experience a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
What the research does NOT say
The pill is a genuine milestone, but a few points keep the picture honest.
Handled honestly, these limits are not a weakness of the research — they are what keep an exciting approval in proper perspective.
Frequently asked questions
Is there a semaglutide pill for weight loss?
Does the pill work as well as the injection?
Does WeightlessRx offer the Wegovy pill?
Is compounded semaglutide the same as the Wegovy pill?
Summary
- In December 2025 the FDA approved the first oral GLP-1 pill for weight loss — a once-daily semaglutide tablet sold as the Wegovy pill by Novo Nordisk — which launched in the U.S. in early January 2026.¹
- In the OASIS 4 trial (64 weeks, 307 adults, diabetes excluded), average weight loss was about 14% on a treatment-policy basis (13.6% vs 2.2% placebo) and about 17% among those who stayed on treatment (16.6% vs 2.7%).³
- The pill is once-daily with specific dosing conditions; the injection is once-weekly. Novo Nordisk describes their effects as comparable, but they were not compared head-to-head.¹ ²
- The Wegovy pill is a brand-name product; WeightlessRx prescribes compounded semaglutide as an injection — the same active ingredient, a different product with a different regulatory status. WeightlessRx does not offer the pill.
- Individual results vary, the most common side effects are gastrointestinal, and long-term real-world data is still accumulating.³
Want to understand semaglutide more broadly?
No pressure and no pricing — just the science and how care works.
Read our complete guide to semaglutide →Curious whether GLP-1 treatment fits you? See how WeightlessRx works →
References & sources
- Novo Nordisk. "FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults." News release, 22 December 2025 (PR Newswire). prnewswire.com
- AJMC. "FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss." December 2025. ajmc.com
- Applied Clinical Trials. "FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results" (OASIS 4 estimands: 16.6% on-treatment vs 2.7% placebo; 13.6% treatment-policy vs 2.2% placebo). December 2025. appliedclinicaltrialsonline.com
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. WeightlessRx is not affiliated with or endorsed by Novo Nordisk or Eli Lilly. WeightlessRx prescribes compounded semaglutide and compounded tirzepatide — the active ingredients, not the brand-name products — and does not prescribe or sell the brand-name Wegovy pill. Compounded medications are prepared by licensed U.S. pharmacies and are not reviewed by the FDA for safety, quality, or efficacy.
Editorial standards & medical oversight
This educational content follows WeightlessRx clinical content standards and is reviewed for accuracy against current obesity-medicine and GLP-1 treatment guidelines, including FDA prescribing information, the American Association of Clinical Endocrinology (AACE) obesity guideline, and peer-reviewed clinical literature. Information is educational and is not medical advice. Treatment eligibility is determined only after a U.S.-licensed clinician in our third-party provider network reviews your intake and medical history. Read our full medical review policy →